Yusheng Ye

168 Changhai Road
Shanghai, 200433, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Definitive radiotherapy for local and metastatic lesions in prostate cancer patients with oligometastases.

Definitive radiotherapy for local and metastatic lesions in prostate cancer patients with oligometastases.

Journal: Frontiers in oncology
Published: July 09, 2025

ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer.

ADJUPANC protocol: a phase III study of adjuvant chemotherapy versus chemoradiotherapy for pancreatic cancer.

Journal: Future oncology (London, England)
Published: June 30, 2025

Central-boost Ablative Radiation Therapy for Solid Tumors: Study Protocol of a Single-arm, Phase II Trial (CBART).

Central-boost Ablative Radiation Therapy for Solid Tumors: Study Protocol of a Single-arm, Phase II Trial (CBART).

Journal: Technology in cancer research & treatment
Published: June 12, 2025

Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer.

Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer.

Journal: Radiation oncology (London, England)
Published: January 10, 2024

Protocol of the integrated boost to the dominant intraprostatic nodule in stereotactic body radiation therapy for localized prostate cancer.

Protocol of the integrated boost to the dominant intraprostatic nodule in stereotactic body radiation therapy for localized prostate cancer.

Journal: Future oncology (London, England)
Published: December 12, 2022

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.

Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.

Journal: BMJ open
Published: September 30, 2022

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial.

Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabine for locally recurrent pancreatic cancer after surgical resection on survival outcomes: A secondary analysis of an open-label, randomised, controlled, phase 2 trial.

Journal: EClinicalMedicine
Published: September 08, 2022

Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial.

Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial.

Journal: BMJ open
Published: August 29, 2022

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.

Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial.

Journal: Cancer control : journal of the Moffitt Cancer Center
Published: August 18, 2022

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.

Journal: The Lancet. Oncology
Published: March 03, 2022

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China.

Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China.

Journal: Frontiers in oncology
Published: February 19, 2022

Optimization of Cas9 RNA sequence to reduce its unexpected effects as a microRNA sponge.

Optimization of Cas9 RNA sequence to reduce its unexpected effects as a microRNA sponge.

Journal: Molecular cancer
Published: December 16, 2021
Showing 1-12 of 17

Last Updated: 09/26/2026